Pharmaceutical company
PharmaDrug Inc. (OTC:LMLLF) which focuses on cannabis, psychedelics and naturally-derived medicines has launched a sponsored research agreement with the University of Michigan to study the psychedelic DMT.
The research will be led by Dr. Jimo Borjigin, in an effort to develop novel therapeutic strategies for DMT using animal models.
“I have a long history in studying DMT, said Dr. Jimo Borjigin. I have dedicated my research in understanding how the brain functions and its effects on the heart in normal and abnormal states that can translate to relevant clinical uses.”
A Pharma Focus on DMT: The company stated that it’s strategy around the pharmaceutical development of psychedelic therapies will revolve around the DMT molecule.
Flexibility allows manufactures to meet the needs of the growing and versatile injectables market.
Mar 4th, 2021
Modular manufacturing is on the rise in the pharmaceutical industry. The last few years have shown an increase of interest in modular solutions for a variety of uses and Stevanato Group–a provider of integrated systems for pharma and healthcare–projects that this tendancy will only continue, especially in injectables.
This popularity is due to the flexibility offered by modular manufacturing, allowing pharmaceutical processors to produce a range of products in a single facility with faster changeovers and improved overall equipment effectiveness (OEE). Modular manufacturing breaks down a system into discrete component “modules” that perform specific roles and can be integrated into or removed from the overall structure at will.